OVCH1 Inhibitors
OVCH1 inhibitors encompass a group of chemical compounds that interact with various signaling pathways, which, in turn, are responsible for regulating the functional activity of OVCH1. Rapamycin, for instance, targets the mTOR pathway, a central controller of cell growth and protein synthesis, thereby exerting an inhibitory effect on OVCH1 by constraining the cellular machinery necessary for its function. LY294002 and Wortmannin both inhibit the PI3K/AKT pathway, reducing the survival and proliferation signals that could otherwise enhance OVCH1 activity. Similarly, U0126 and PD98059 impede the MEK/ERK pathway, which can intersect with signaling pathways regulating OVCH1, thus potentially curtailing its activity by lessening regulatory kinase activity.
Other inhibitors like SB203580 and SP600125 target the p38 MAPK andJNK respectively, attenuating stress response pathways that OVCH1 may be activated by. Inhibition by these compounds could lead to a reduction in OVCH1 activity as it is deprived of stimulatory signals from these pathways. Bortezomib, as a proteasome inhibitor, can indirectly inhibit OVCH1 by inducing cellular stress through accumulation of misfolded proteins, potentially overwhelming the degradation pathways OVCH1 is associated with. Dasatinib and Sunitinib, through their broad inhibition of tyrosine kinases, including Src family kinases and receptor tyrosine kinases involved in various growth and survival pathways, can modulate downstream signaling events, which may decrease the activity of OVCH1. Sorafenib's inhibition of the RAF/MEK/ERK pathway, and Triciribine's targeting of AKT activation, further exemplify the diverse mechanisms through which these chemicals can indirectly lead to the inhibition of OVCH1 by modulating the signaling cascades that influence its function.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits the mTOR pathway, which is crucial for protein translation and cell proliferation. Since OVCH1 is involved in cellular growth processes, the inhibition of mTOR can lead to decreased activity of OVCH1 by limiting the protein synthesis machinery that is necessary for OVCH1 function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that prevents the phosphorylation and activation of AKT, downstream of PI3K. AKT influences many proteins involved in survival and growth, including OVCH1. Inhibiting PI3K/AKT pathway can reduce the functional activity of OVCH1 by decreasing survival signals that OVCH1 may rely on. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin acts similarly to LY294002 by inhibiting PI3K, leading to reduced AKT activation. The decreased AKT activity can lower the activity of proteins that are regulated by the PI3K/AKT pathway, including OVCH1, thereby diminishing OVCH1's functional output. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is another MEK inhibitor that prevents activation of ERK. By inhibiting MEK, PD98059 can suppress the downstream signaling that may be involved in the regulation of OVCH1 activity, resulting in decreased action of OVCH1. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. The p38 MAPK pathway is involved in stress responses and apoptosis. Inhibiting p38 MAPK can indirectly lead to the inhibition of OVCH1 by reducing the stress-induced signaling pathways that could enhance OVCH1 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of stress response pathways. Inhibition of JNK can decrease the functional activity of OVCH1 by inhibiting stress signaling pathways that may activate OVCH1. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that can lead to the accumulation of misfolded proteins, inducing stress responses. This can indirectly inhibit OVCH1 by overwhelming the protein degradation pathways OVCH1 may be involved in, reducing its functional capacity. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine specifically inhibits the activation of AKT. By decreasing AKT activity, triciribine can lead to an indirect inhibition of OVCH1 by affecting the cellular growth and survival pathways where OVCH1 might have a role. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor with broad specificity. It can inhibit Src family kinases that play a role in various signaling pathways associated with cell growth and survival, potentially lowering OVCH1 activity by altering signaling cascades that OVCH1 is involved in. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a RAF inhibitor that can block the RAF/MEK/ERK signaling pathway. As OVCH1 activity could be modulated by this pathway, its inhibition by sorafenib can lead to reduced OVCH1 functional activity. | ||||||